Press coverage about Aratana Therapeutics (NASDAQ:PETX) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aratana Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.5452151110444 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Contrasting ProMetic Life Sciences (PFSCF) and Aratana Therapeutics (PETX) (americanbankingnews.com)
- Ernst Heinen Sells 2,674 Shares of Aratana Therapeutics Inc (PETX) Stock (americanbankingnews.com)
- Aratana Therapeutics Inc (PETX) Insider Sells $23,834.20 in Stock (americanbankingnews.com)
- Aratana Therapeutics, Inc. (PETX) locked -0.41% below comparative SMA-200 (nasdaqplace.com)
- Active Daily Watch List: Aratana Therapeutics, Inc. (PETX), Orthofix International NV (OFIX) (newsregistrar.com)
Shares of NASDAQ:PETX traded up $0.06 on Friday, hitting $5.14. The company’s stock had a trading volume of 211,201 shares, compared to its average volume of 250,932. Aratana Therapeutics has a 1 year low of $3.67 and a 1 year high of $7.28. The stock has a market cap of $241.69 million, a P/E ratio of -5.29 and a beta of 2.78. The company has a quick ratio of 2.82, a current ratio of 3.02 and a debt-to-equity ratio of 0.09.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. The firm had revenue of $4.91 million for the quarter, compared to analyst estimates of $4.72 million. Aratana Therapeutics had a negative return on equity of 35.25% and a negative net margin of 154.23%. equities research analysts expect that Aratana Therapeutics will post -0.48 EPS for the current fiscal year.
Several analysts have weighed in on PETX shares. Stifel Nicolaus lowered their price target on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, August 6th. BidaskClub raised Aratana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, May 10th. HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the company a “buy” rating in a report on Monday, May 7th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 15th. Finally, Zacks Investment Research raised Aratana Therapeutics from a “sell” rating to a “hold” rating and set a $5.50 price target on the stock in a report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Aratana Therapeutics presently has an average rating of “Buy” and a consensus target price of $8.21.
In other news, insider Peter Steven St sold 11,513 shares of the stock in a transaction dated Monday, July 30th. The stock was sold at an average price of $4.33, for a total transaction of $49,851.29. Following the transaction, the insider now directly owns 649,233 shares in the company, valued at approximately $2,811,178.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Brent Standridge sold 10,000 shares of the stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $4.56, for a total value of $45,600.00. Following the transaction, the chief operating officer now owns 99,967 shares in the company, valued at $455,849.52. The disclosure for this sale can be found here. Insiders have sold a total of 28,815 shares of company stock worth $133,057 over the last quarter. Corporate insiders own 5.30% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
Featured Article: What is the NASDAQ Stock Market?
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.